Ligand Pharmaceuticals Incorpor Earnings: Your Sneak Peek to the Big Announcement

Ligand Pharmaceuticals Incorpor (NASDAQ:LGND) will report earnings after markets close on Wednesday, May 8th. Ligand Pharmaceuticals Incorporated develops drugs which regulate hormone activated intracellular receptors. These receptors play a role in regulating the genetic processes affecting diseases such as gynecological disorders, certain cancers, as well as cardiovascular, inflammatory, and skin diseases.

Here is your Cheat Sheet to Ligand Pharmaceuticals Incorpor Earnings:

Earnings Expectations: Analysts expect earnings of $0.09 per share on revenues of $10.00 million.

Analyst Trends:

Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a profit of $0.07 to a profit $0.04. For the current year, the average estimate is a profit of $0.46, which is better than the estimate ninety days ago.

Earnings Trends:

Here’s how Ligand Pharmaceuticals Incorpor has been performing on an annual basis:

Fiscal Year 2008 2009 2010 2011 2012
Revenue ($) in millions 27.32 38.94 23.54 30.04 31.39
Diluted EPS ($) -6.180 -0.10 -0.53 0.49 -0.03

Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:

Quarter Dec. 31, 2011 Mar. 31, 2012 Jun. 30, 2012 Sep. 30, 2012 Dec. 31, 2012
Revenue ($) in millions 12.94 5.64 5.74 6.38 13.64
Diluted EPS ($) 0.2367 0.06 -0.13 -0.01 0.0531

Past Performance:
Ligand Pharmaceuticals Incorpor has beat analyst estimates 2 times in the past four quarters. This is not consistent enough to get bullish yet.

“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at]